Summary
Bonitas Research LLC, an activist short research firm, has published a detailed report expressing significant concerns about Harrow Health Inc (Nasdaq: HROW), a pharmaceutical company specializing in ophthalmic prescription drugs. The report highlights regulatory, legal, and business risks that could negatively impact Harrow Health's stock and operations.
Who is Harrow Health, Inc.
Harrow Health, Inc. is a U.S.-based specialty pharmaceutical company primarily engaged in selling ophthalmic prescription pharmaceuticals through its ImprimisRx brand. It historically operated as a bespoke compound pharmacy, blending custom drugs at its facilities. Over recent years, it has tried to transition into a pharmaceutical development company through strategic deals, acquisitions of licensed drugs from Novartis, and FDA approvals of new products such as Iheezo. Despite these efforts, Harrow faces operational, regulatory, and market challenges undermining its growth story.
Key Points from Report
DOJ Investigation Shadows Dexycu Sales
- Since August 2022, the U.S. Department of Justice has investigated Dexycu sales, marketing, and promotional practices—activities overseen by Harrow but undisclosed to investors.
- Harrow took full control of Dexycu sales and marketing in early 2022, bearing responsibility for compliance, yet kept the DOJ subpoena hidden despite Eyepoint Pharmaceuticals’ public disclosure.
Unsanitary Conditions and FDA Warning Letters
- Harrow’s two New Jersey-based compound pharmacy facilities have faced multiple FDA inspections, leading to warning letters citing unsanitary conditions, false marketing claims, and product recalls.
- A nationwide recall was issued in late 2022 for a Timolol-Latanoprost product due to sub-potency, and ongoing regulatory meetings suggest persistent FDA scrutiny over Harrow’s compounding operations.
Declining Rx Growth for Licensed Novartis Drugs
- Harrow’s acquisition of nine licensed drugs from Novartis has not delivered growth; prescription (Rx) unit counts for drugs like Iopidine, Moxeza, and Maxitrol have declined or remained flat despite industry category rebounds.
- The licensed drugs represent unpopular legacy products facing strong competition from branded and generic alternatives, limiting Harrow’s commercial success in these categories.
Iheezo’s Tough Market Entry
- Iheezo, approved by the FDA in 2022 as the first branded ocular anesthetic in 14 years, is based on a compound originally FDA-approved in 1955 and faces well-established competitors in a mature market with little growth potential.
- Significant marketing efforts and investment from Harrow will be necessary for Iheezo to challenge entrenched products like proparacaine and lidocaine.
Off-Balance Sheet Spin-Offs Dragging on Financials
- Harrow’s investments into off-balance sheet subsidiaries have led to substantial losses, notably Surface Ophthalics written down to zero and Melt Pharmaceuticals struggling with halted IPO plans.
- Key executives hold positions and stock in these spin-offs, raising conflict of interest concerns and suggesting insider enrichment at the expense of minority shareholders.
Activ8 Finance Analysis
The Bonitas Research report raises substantial red flags about Harrow Health’s business practices, regulatory compliance, and financial integrity. The undisclosed DOJ investigation and ongoing FDA scrutiny highlight significant legal and operational risks potentially undermining investor confidence and the company’s long-term viability.
Investors should consider these revelations in the context of Harrow’s challenged growth outlook, lackluster performance of licensed drug portfolios, and losses tied to off-balance sheet ventures. These factors collectively suggest caution in assessing Harrow Health’s future trajectory and valuation.